Literature DB >> 14596430

Rate, pattern and factors related to damage in Brazilian systemic lupus erythematosus patients.

Márcio Soares1, L Reis, J A S Papi, C R L Cardoso.   

Abstract

The Systemic Lupus International Collaborating Clinics/American College of Rheumatology (ACR) Damage Index (SDI) is an accepted instrument to ascertain damage. It has been shown to vary among different SLE populations. The aim of this study was to assess SDI score, pattern and factors related to damage in Brazilian SLE outpatients. The SDI was obtained in 105 patients with a median age of 41 (5-95%, 19-61.7) years and a median SLE duration of 127 (17.6-345.9) months. Patients had a median SDI of 2 (0-8) and 81.9% had some damage (SDI > 0). Damage was associated with a higher number of ACR criteria for SLE in multivariate analysis (OR = 2.32, 95%CI = 1.23-4.37, P = 0.009). Antiphospholipid syndrome (APS) (OR = 9.82, 95%CI = 2.74-35.23, P < 0.001), methylprednisolone pulses (OR = 3.91, 95%CI = 1.19-12.81, P = 0.024), age (OR = 1.70, 95%CI = 1.02-1.13, P = 0.011) and prednisone use duration (OR = 1.01, 95%CI = 1.002-1.02, P = 0.020) were related to severe damage (SDI > or = 4). Hypertension was associated with renal, cardiac and atherosclerotic damage, as cyclophosphamide pulses were with premature menopause. In conclusion, damage was very frequent in Brazilian SLE patients, mainly due to skin involvement, compared to other SLE populations. The presence of APS was the major independent contributor to the development of severe damage. Arterial hypertension was identified as a common risk factor for renal, cardiac and atherosclerotic damage.

Entities:  

Mesh:

Year:  2003        PMID: 14596430     DOI: 10.1191/0961203303lu447xx

Source DB:  PubMed          Journal:  Lupus        ISSN: 0961-2033            Impact factor:   2.911


  5 in total

1.  Possible protective effect of hydroxychloroquine on delaying the occurrence of integument damage in lupus: LXXI, data from a multiethnic cohort.

Authors:  Guillermo J Pons-Estel; Graciela S Alarcón; Luis A González; Jie Zhang; Luis M Vilá; John D Reveille; Gerald McGwin
Journal:  Arthritis Care Res (Hoboken)       Date:  2010-03       Impact factor: 4.794

2.  Evaluation of damage index and its association with risk factors in patients with systemic lupus erythematosus.

Authors:  Zahra Sayed Bonakdar; Negin Mohtasham; Mansoor Karimifar
Journal:  J Res Med Sci       Date:  2011-03       Impact factor: 1.852

3.  The coexistence of antiphospholipid syndrome and systemic lupus erythematosus in Colombians.

Authors:  Juan-Sebastian Franco; Nicolás Molano-González; Monica Rodríguez-Jiménez; Yeny Acosta-Ampudia; Rubén D Mantilla; Jenny Amaya-Amaya; Adriana Rojas-Villarraga; Juan-Manuel Anaya
Journal:  PLoS One       Date:  2014-10-24       Impact factor: 3.240

4.  Cardiovascular disease in latin american patients with systemic lupus erythematosus: a cross-sectional study and a systematic review.

Authors:  Jenny Amaya-Amaya; Juan Camilo Sarmiento-Monroy; Julián Caro-Moreno; Nicolás Molano-González; Rubén D Mantilla; Adriana Rojas-Villarraga; Juan-Manuel Anaya
Journal:  Autoimmune Dis       Date:  2013-11-03

Review 5.  Cardiovascular involvement in autoimmune diseases.

Authors:  Jenny Amaya-Amaya; Laura Montoya-Sánchez; Adriana Rojas-Villarraga
Journal:  Biomed Res Int       Date:  2014-07-22       Impact factor: 3.411

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.